{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T13:49:12Z","timestamp":1713966552783},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["MMW Fortschr Med"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s15006-023-3509-4","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:06:10Z","timestamp":1711065970000},"page":"68-75","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Medikament\u00f6se Therapie der Herzinsuffizienz","Medical treatment of patients with congestive heart failure"],"prefix":"10.1007","volume":"166","author":[{"given":"Robert H. G.","family":"Schwinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,22]]},"reference":[{"key":"3509_CR6468","doi-asserted-by":"crossref","unstructured":"McDonagh TA et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42: 3599-726","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"3509_CR6474","doi-asserted-by":"crossref","unstructured":"McDonagh TA et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023: ehad195","DOI":"10.15829\/1560-4071-2023-5168"},{"key":"3509_CR6478","doi-asserted-by":"crossref","unstructured":"Soltani S et al. Fr\u00fche Implementierung der \u201eFantastic four\u201c bei Herzinsuffizienz mit reduzierter EjektionsfraktionLeitliniengerechte medikament\u00f6se Therapie - Ein praktischer Leitfaden. DMW. 2022; 147: 931-8","DOI":"10.1055\/a-1760-3843"},{"key":"3509_CR6490","doi-asserted-by":"crossref","unstructured":"Abdin A et al. A practical approach to the guideline-directed pharmacological treatment of heart failure with reduced ejection fraction. ESC Heart Fail. 2023; 10: 24-31. doi: 10.1002\/ehf2.14197","DOI":"10.1002\/ehf2.14197"},{"key":"3509_CR6563","doi-asserted-by":"crossref","unstructured":"Zannad F et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020; 396: 819-29","DOI":"10.1016\/S0140-6736(20)31824-9"},{"key":"3509_CR6567","doi-asserted-by":"crossref","unstructured":"Docherty KF et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J. 2020; 41: 2379-92","DOI":"10.1093\/eurheartj\/ehaa183"},{"key":"3509_CR6496","doi-asserted-by":"crossref","unstructured":"Shen L et al. Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: An analysis of DAPA-HF. JACC Heart Fail. 2021; 9: 254-64","DOI":"10.1016\/j.jchf.2020.11.009"},{"key":"3509_CR6575","doi-asserted-by":"crossref","unstructured":"Desai AS et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the approach to treatment of heart failure PARADIGM-HF trial. JAMA Cardiol. 2017; 2: 79-85","DOI":"10.1001\/jamacardio.2016.4733"},{"key":"3509_CR6500","doi-asserted-by":"crossref","unstructured":"Maximilian W, Schwinger RHG. Repetitive Therapie mit Levosimendan reduziert NT-proBNP und verbessert NYHA-Klasse: Ein Fallbericht. Aktuelle Kardiologie. 2022; 11: 484-9","DOI":"10.1055\/a-1799-7077"}],"container-title":["MMW - Fortschritte der Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15006-023-3509-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15006-023-3509-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15006-023-3509-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:24:11Z","timestamp":1711067051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.springermedizin.de\/doi\/10.1007\/s15006-023-3509-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["3509"],"URL":"https:\/\/doi.org\/10.1007\/s15006-023-3509-4","relation":{},"ISSN":["1438-3276","1613-3560"],"issn-type":[{"value":"1438-3276","type":"print"},{"value":"1613-3560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"22 March 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Der Autor erkl\u00e4rt, dass er sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten lie\u00df. Er legt folgende potenzielle Interessenkonflikte offen: keine.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Der Verlag erkl\u00e4rt, dass die inhaltliche Qualit\u00e4t des Beitrags durch zwei unabh\u00e4ngige Gutachten best\u00e4tigt wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere f\u00fcr Pr\u00e4parate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}